# TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435

> **NCT01046058** · PHASE1 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 23 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

- **DRUG:** TMC435

## Key facts

- **NCT ID:** NCT01046058
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2013-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01046058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01046058, "TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01046058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*